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Abstract
Background: Some studies have suggested an association between omega-3 long-chain polyunsaturated fatty
acids (n-3 LC PUFAs) and better cognitive outcomes in older adults. To date, only two randomised, controlled trials
have assessed the effect of n-3 LC PUFA supplementation on cognitive function in older cognitively healthy
populations. Of these trials only one found a benefit, in the subgroup carrying the ApoE-ε4 allele. The benefits of
n-3 LC PUFA supplementation on cognitive function in older normal populations thus still remain unclear. The
main objective of the current study was to provide a comprehensive assessment of the potential of n-3 LC PUFAs
to slow cognitive decline in normal elderly people, and included ApoE-ε4 allele carriage as a potential moderating
factor. The detailed methodology of the trial is reported herein.
Methods: The study was a parallel, 18-month, randomised, double-blind, placebo-controlled intervention with
assessment at baseline and repeated 6-monthly. Participants (N = 391, 53.7% female) aged 65-90 years, English-
speaking and with normal cognitive function, were recruited from metropolitan Adelaide, South Australia.
Participants in the intervention arm received capsules containing fish-oil at a daily dosage of 1720 mg of
docosahexaenoic acid and 600 mg of eicosapentaenoic acid while the placebo arm received the equivalent
amount of olive oil in their capsules. The primary outcome is rate of change in cognitive performance, as
measured by latent variables for the cognitive constructs (encompassing Reasoning, Working Memory, Short-term
Memory, Retrieval Fluency, Inhibition, Simple and Choice-Reaction Time, Perceptual Speed, Odd-man-out Reaction
Time, Speed of Memory Scanning, and Psychomotor Speed) and assessed by latent growth curve modeling.
Secondary outcomes are change in the Mini-mental State Examination, functional capacity and well-being
(including health status, depression, mood, and self-report cognitive functioning), blood pressure, and biomarkers
of n-3 LC PUFA status, glucose, lipid metabolism, inflammation, oxidative stress, and DNA damage.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12607000278437
* Correspondence: vanessa.danthiir@csiro.au
† Contributed equally
1Preventative Health Research Flagship, Commonwealth Scientific and
Industrial Research Organisation - Food and Nutritional Sciences, Adelaide,
South Australia, Australia
Full list of author information is available at the end of the article
Danthiir et al. Nutrition Journal 2011, 10:117
http://www.nutritionj.com/content/10/1/117
© 2011 Danthiir et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Ageing is accompanied by what is normally considered
to be inevitable cognitive decline, although the extent to
which this occurs is highly variable, and strongly
affected by various disease processes. Cognitive function
is a major determinant of quality of life in older age and
decline in cognitive functioning is a primary contribut-
ing factor to increasing dependency in the elderly. Due
to the ageing profile of the population, the financial,
social, and other burdens that this dependency places
upon society are of increasing concern. Thus, finding
ways to prevent or ameliorate age-related cognitive
decline is a public health imperative, with potential ben-
efits not just in terms of lessening aged care costs but
also in the enhancement of well-being in a growing seg-
ment of society.
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are
one diet-related factor suggested to influence cognitive
decline during ageing. The n-3 long-chain (LC) PUFAs
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are crucial to brain development and normal
brain functioning [1]. DHA is particularly important to
brain functioning due to its influence on neural mem-
brane properties, which modulate cell signalling [2].
DHA concentration in the brain decreases with age in
humans [3] and rats [4]; this has been postulated to be
consequential to the age-related deterioration in central
nervous system functions [3]. Evidence from animal stu-
dies supports this; animals fed a low n-3 PUFA diet
show cognitive deficits [4,5] that are ameliorated by
DHA supplementation [6,7] and DHA supplementation
improves memory performance in aged mice [8].
Cross-sectional and prospective studies
Oily fish are the major dietary source of the n-3 LC
PUFAs, EPA and DHA. A consistent finding across stu-
dies is that higher intake of fish is related to less cogni-
tive decline [9-12] and incidence of dementia [10,13,14]
in prospective studies, and associated with better cogni-
tive performance in non-clinical samples [11,15-17], in
cross-sectional analyses. However, variable associations
have been found between dietary intake levels of n-3 LC
PUFAs and cognitive outcomes; only a handful of the
aforementioned studies that also examined relationships
between cognitive outcomes and dietary intake levels of
n-3 LC PUFAs have found significant positive relation-
ships [9,14,15].
Stronger evidence of a positive relationship between
cognitive outcomes in older age and levels of n-3 LC
PUFAs has been found in studies assessing plasma or
erythrocyte levels of n-3 PUFAs. In these studies, DHA
and EPA levels, either individually or in combination,
have been associated with better cognitive function in
normal older adults in cross-sectional analyses [18,19],
and in prospective studies, with better cognitive out-
comes over time [19] or reduced risk of cognitive
decline [20], and lower risk of developing dementia [21];
in contrast, Laurin et al [22] reported a negative rela-
tionship between cognition and biomarkers of n-3 LC
PUFAs.
Randomised controlled trials (RCTs)
There have been six published double-blind RCTs of n-
3 LC PUFAs on cognitive functioning in the elderly
within both clinical and non-clinical populations
[23-28]. Only two studies have been conducted with
cognitively healthy populations, screened for dementia
at baseline, and no overall effect of supplementation was
found. The “Older People and n-3 Long-chain polyunsa-
turated fatty acids” study [24] supplemented 867 cogni-
tively healthy participants aged 70-79 years, with either
200 mg of EPA and 500 mg of DHA, or olive oil, daily
for 24 months. After adjustment for confounders, there
was no significant difference between the groups in per-
formance on the California Verbal Learning Test, the
main cognitive outcome measure, or any secondary cog-
nitive outcomes (a global cognitive score, and domain
scores on memory, processing speed, executive function,
and delayed recall). In a 26-week RCT of fish oil on cog-
nitive performance in 302 cognitively healthy adults
aged 65+ years [27], no main effect of supplementation
was seen for any of the cognitive domains (attention,
sensorimotor speed, memory, and executive function),
assessed by 5 tests. However, subgroup analysis revealed
that carriers of the Apolipoprotein E (ApoE) ε4 allele, in
both the low (226 mg EPA, 176 mg DHA) and high
dose (1093 mg EPA, 847 mg DHA) fish oil groups,
showed an improvement after 26 weeks compared with
the placebo on the Digit-Span Forward task, their mar-
ker of attention.
In three of the studies with cognitively impaired
(including Alzheimer’s disease (AD)) samples, the inter-
ventions had a beneficial effect on cognitive outcomes
but only in participants with mild cognitive dysfunction
[23,25,28]. This finding was not replicated in a large
RCT conducted over 18 months of 402 participants with
mild to moderate AD. However, in this study in ApoE-
ε4 non-carriers only, there was a positive effect on two
cognitive outcome measures [26].
Apolipoprotein E-ε4 allele
The presence or absence of the Apolipoprotein E-ε4
allele appears to be a potentially important modifier of
relationships between n-3 LC PUFAs and older-age cog-
nitive outcomes but there are conflicting findings
regarding the direction of this interaction. Epidemiologi-
cal studies that have reported a differential relationship
between cognitive outcomes and measures of n-3 LC
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PUFAs for carriers versus non-carriers of the ApoE-ε4
allele have found a beneficial relationship present only
in non-carriers [19,29]. However, the two RCTs that
have included examination of the effect of ApoE-ε4
allele carriage in sub-analyses have reported a beneficial
effect of supplementation dependent on ApoE-ε4 allele
status, but differ on which group benefits from supple-
mentation [26,27]. Nonetheless, ApoE polymorphisms
have been found to influence lipid responses to fish oil
supplementation [30] and in a small group of males,
those without ApoE-ε4 showed a greater increase in
DHA and EPA after fish-oil supplementation [31].
Further, possession of the ApoE-ε4 allele is associated
with worse cognitive performance in old age [32] and
greater risk of cognitive decline and dementia [33],
hence, even in cognitively healthy samples screened for
dementia, the genesis of any cognitive change may differ
between carriers and non-carriers, providing another
potential avenue for differential effects of supplementa-
tion on cognitive outcomes due to ApoE genotype.
These studies suggest that n-3 LC PUFA intake, in
particular DHA, has a beneficial effect on cognition in
older adults. However, the majority of evidence for the
benefits of n-3 PUFA on cognitive functioning in adults
is associational. Furthermore, work to date in this area
has often not comprehensively assessed cognitive func-
tion or cognitive decline. Without a priori expectations
of specific cognitive domains that will be affected, a
comprehensive operationalisation of cognition is
required in order to ascertain whether a null result is
due to the absence of a relationship or effect, or the
relevant cognitive domains were not assessed. Given the
potential importance of ApoE-ε4 allele carriage as a
determinant of n-3 LC PUFAs influence upon cognitive
outcomes in older age, more randomised controlled
trials are needed that incorporate consideration of its
impact in order to determine whether n-3 LC PUFAs
can influence age-related cognitive change in older
adults.
Methods/Design
The primary aim of the current trial was to comprehen-
sively assess over 18-months the efficacy of a DHA-rich
fish-oil supplement on slowing cognitive decline in non-
demented older adults; the hypothesis was that, over 18
months, the n-3 LC PUFA supplementation group
would show slower cognitive decline than the control
group. The trial was set within the broader context of
examining nutritional, health, and lifestyle factors asso-
ciated with better cognitive and well-being outcomes in
the elderly, both cross-sectionally and longitudinally.
Secondary aims were: 1) to explore relationships
between measures of n-3 LC PUFA intake and measures
of cognitive function at baseline; 2) to determine
whether the effect of n-3 LC PUFA supplementation on
cognitive decline is moderated by presence of the ApoE-
ε4 allele, initial cognitive status, measures of dietary n-3
LC PUFA intake (including changes in n-3 LC PUFA
status) or any nutritional, health-related, or psychologi-
cal factors associated with cognitive outcomes in the
elderly; 3) to examine the effect of the intervention on
measures of functional capacity and well-being; and 4)
examine relationships between measures of n-3 LC
PUFA intake and functional capacity and well-being at
baseline.
This paper details the methodology of the study,
including the design, assessment battery, and research
protocols used.
Study design
The trial was a parallel, 18-month, randomised, double-
blind, placebo-controlled trial with repeated measures
every 6 months, totalling 4 measurement points.
Because the primary hypothesis related to change in a
continual developmental process, multiple repeated
measures enable determination of the rate of change on
the measures, allowing assessment of an intervention
effect on a trajectory, rather than effects at a specific
time point. Decline of the cognitive abilities vulnerable
to ageing effects begins by the early 30s so although par-
ticipants were screened for cognitive impairment, all
were expected to experience cognitive decline to some
extent; for instance, meta-analyses of cross-sectional
data suggest that processing speed declines, on average,
by approximately 20% at age 40 and by 40-60% at age
80 [34]. In terms of supplementation duration, studies
have detected significant cognitive changes due to n-3
PUFA supplementation after 3-4 months [35,36]. How-
ever, these studies focused on clinical populations;
change in normal populations would not be expected to
be as rapid, or of the same magnitude and the longer
duration allowed for the multiple testing points required
to best test the hypothesis and conferred greater power
to detect an effect.
The trial was co-ordinated from CSIRO Food and
Nutritional Sciences, Adelaide, Australia. The protocol
was explained to participants and written informed con-
sent was obtained prior to study commencement. All
experimental procedures were approved by the Human
Research Ethics Committee of CSIRO and in compli-
ance with the Helsinki declaration. The study follows
Good Clinical Research Practice. Participants were
encouraged to inform the trial research officer of any
adverse events; these were recorded by the officer.
Adverse effects suspected as being related to supplement
use were reported to the trial clinical doctor for follow-
up. Participants attended the centre every 3 months;
every 6 months, to undergo their assessments, and 3-
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months after each assessment to obtain additional cap-
sules and be followed-up. At these visits, adverse events
were recorded, along with any changes in medication,
supplement use, or general health.
Participant recruitment
Sampling and criteria
Participants were recruited from metropolitan Adelaide,
South Australia and surrounding areas via agencies and
organisations for older citizens, public advertisements,
and media releases. Information sheets explaining the
study and asking for volunteers, were circulated in
response to expressions of interest. To be eligible for
inclusion, participants were required to be 65-90 years
of age at screening, fluent in English, and agree to not
commence their own n-3 fish-oil (or algal) supplementa-
tion throughout the duration of the study. Participants
were excluded from study entry if they were taking n-3
fish-oil (or algal) supplements, had experienced any con-
dition where cognitive impairment may be a conse-
quence (e.g., head injury, other brain trauma, transient
ischemic attacks, stroke, coronary artery bypass surgery,
open heart surgery, degenerative neurological disease,
history of alcohol/drug abuse), were taking doses of
medications known to interfere with cognition, had a
significant medical condition, were diagnosed with an
intellectual disability, current major clinical depression,
diabetes, dementia, or received a score less than 22/27
on a telephone-administered version [37] of the Mini-
mental State Examination (MMSE) (equivalent to < 24/
30 on the standard MMSE, the traditional cut-off for
possible dementia).
Screening and information sessions
Individuals who expressed interest in participating were
sent a questionnaire to obtain demographic information,
history of health events, and specific questions to deter-
mine eligibility. Participants deemed eligible, based on
the questionnaire responses, were contacted by a trained
research officer and, if consenting, were administered a
version of the MMSE via telephone - this method of
administration has been validated for the MMSE [37].
Participants scoring less than 22 correct out of a poten-
tial 27 points were excluded. Subsequently, approxi-
mately two to three months prior to baseline testing,
participants attended an information session, during
which the study protocol and requirements were
explained to them, queries were answered, and practice
trials and examples of the cognitive tasks were given.
Participants were asked to maintain their usual diet over
the course of the study. After written consent to partici-
pate was obtained, individual administration of the stan-
dard MMSE was undertaken, to corroborate the
telephone screening and to serve as an outcome
measure.
Randomisation, allocation, and blinding
Participants were given a unique study number on entry
into the trial. An independent researcher prepared allo-
cation to treatment. Age-stratified, permuted-block ran-
domisation, with mixed block-sizes ranging from two to
eight (size unknown to study investigators until unblind-
ing), with 1:1 allocation was employed. Participants were
placed into 5-year age strata, and randomisation for
each stratum followed a computer generated randomisa-
tion schedule. The researchers, project staff, and partici-
pants remained blinded to treatment allocation until the
trial was completed and the database locked. Capsule
bottles were labelled with participants’ unique study
numbers by an external company. Active and placebo
capsules (opaque brown, oblong, and softgel; Black-
mores Pty Ltd, Australia) and containers were visually
identical, the fish-oil was the low-odour type, and 1%
fish-oil was added to the placebo oil to help maintain
blinding in the event of, for example, accidental piercing
of the capsules or an aftertaste. At the study-end, parti-
cipants were asked to guess which study arm they were
in, to assess adequacy of blinding.
Dietary intervention
Dietary intervention schedule
The intervention was administered for 18 months, start-
ing immediately after baseline assessment, after which
participants received their first 3-month supply of cap-
sule bottles. For the study duration, participants
returned to the CSIRO clinic every 3 months, received
their next 3-month supply of capsules, and returned all
unused capsules. The trial research officers recorded any
reported side-effects of the capsules.
Compliance
Compliance was monitored via a count of all unused
supplements returned at three-monthly intervals, along
with self-report calendars, mailed back on a monthly
basis throughout the trial. If participants’ compliance
fell below 85% on the basis of their calendars, they were
contacted by a research officer who noted the reasons.
Compliance also will be assessed by examination of ery-
throcyte membrane n-3 LC PUFA status and changes in
status, via a blood sample taken at every 6 month-
assessment.
n-3 LC PUFA capsule
The supplement was chosen to be DHA-rich on the
basis that evidence suggests DHA is more related to
cognition in ageing, than is EPA. The dosage for the
current trial followed that of the first reported n-3 LC
PUFA placebo-controlled intervention study focusing on
cognitive decline in the elderly (albeit in AD patients
[25]) that found a positive effect; hence, the study dose
was 1720 mg DHA and 600 mg EPA daily. Each capsule
contained 430 mg DHA and 150 mg EPA (EPAX 1050
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TG/N n-3 concentrate, EPAX, Norway); participants
were instructed to have a total of four capsules a day,
two in the morning and two in the evening. The total
n-3 LC PUFAs in the daily supplement were equivalent
to approximately 150 g of salmon. There are no known
risks associated with n-3 LC PUFA consumption at this
level. Evidence supports the effectiveness of n-3 fish-oil
supplements as providers of n-3 LC PUFAs, with n-3
LC PUFAs from fish-oil supplements being incorporated
into erythrocyte membranes to a similar extent as n-3
LC PUFAs from dietary fish intake [38].
Placebo capsule
The placebo arm received capsules, each containing 990
mg of olive oil (Oil Seed Products, New Zealand) and
10 mg of fish oil (equivalent to 1.8 mg EPA and 1.2 mg
DHA; omega-3 18/12, Ocean Nutrition, Canada) and
consumed a total of 4 capsules a day. Unlike other oils,
olive oil is not rich in n-3 or n-6 fatty acids and should
thus have minimal effect on the n-6:n-3 ratio. Olive oil
is high in mono-unsaturated fatty acids (MUFAs), which
have in some epidemiological studies been associated
with lower cognitive decline [39], yet it is thought that
it is the polyphenolic content of the oil that might bear
this effect. The amount of MUFAs in the capsules was
very minor compared to the dietary consumption of
MUFAs in those studies that found a cognitively protec-
tive effect (i.e., mean daily MUFA intake = 42.1 g [39]).
The 4 g of low-polyphenol olive oil per day was thus
considered non-problematic. The minimal amount of
fish oil was added to help mask any difference between
the placebo and active capsules and was not processed
under nitrogen, rendering it less potent than that used
in the active formulation.
Assessment Administration
After the group information session, participants were
scheduled one visit to the laboratory for assessment,
every 6 months, for 18 months. Self-report question-
naires (see following section on study instruments) were
mailed out to participants up to four weeks prior to
each assessment visit, with instructions to complete and
return them between one to two weeks prior to their
assessment. Missing data or incorrectly completed ques-
tionnaires were thus identified beforehand and
addressed during their assessment sessions. All physical
measurements and cognitive testing were conducted at
the same time in the morning at each session.
For each assessment visit, participants attended the
clinic after an overnight fast, and a blood sample and
physical measurements (height (at baseline only), weight,
and blood pressure) were undertaken by trained phlebo-
tomists and staff. Participants were then given a standar-
dised breakfast in the centre, prior to undertaking the
cognitive test battery. At baseline and final assessment,
blood was taken for measurement of the following. Car-
otenoids, folate, and vitamin B12, were assessed, all hav-
ing been associated with cognitive functioning in the
elderly; this enables examination of cross-sectional asso-
ciations between these measures and outcomes, and if
necessary in the intervention analyses, to control for any
potential differences between groups at baseline or any
changes in these measures that differ between groups
(despite randomisation). Glucose, glycated haemoglobin
(HbA1c), lipid concentrations (total cholesterol, high-
density lipoprotein (HDL), low-density lipoprotein
(LDL), and triglycerides), and homocysteine were also
measured at baseline and final assessment, because of
associations between abnormalities in these parameters
of metabolism and cognitive dysfunction [30]. Inclusion
of these measures allows us to control for possible base-
line differences between groups and potentially assess
whether any changes on these measures due to the
intervention mediate changes on the main outcome vari-
ables. Finally, our blood-derived measures included a
high sensitivity assay for C-reactive protein (CRP), an
inflammatory marker, plasma malondialdehyde (MDA),
a marker of oxidative stress, and telomere length, a mar-
ker of oxidative stress and DNA damage. Oxidative
stress and inflammation have been associated with cog-
nitive decline or impairment [40,41] and are two postu-
lated mechanisms through which n-3 LC PUFAs may
exert an effect on cognitive functioning [34,35]; thus, we
will examine cross-sectional associations between these
measures and our cognitive outcomes, be able to control
for potential differences between groups at baseline, and
assess whether any changes due to fish oil supplementa-
tion mediate any change on the primary outcomes. Apo-
lipoprotein E (ApoE) genotyping was also conducted in
order to examine any differential effect of treatment due
to carriage of the ApoE-ε4 allele. Blood was taken at the
second and third assessment points in order to assess
erythrocyte membrane fatty acid composition at each
time point. n-3 LC PUFA status will be used to assess
compliance/uptake post-hoc and we will also assess
whether changes in n-3 LC PUFA status are associated
with any changes on our outcomes. EPA levels in ery-
throcytes reflect intake over the past month or two,
change linearly with dosage (up to 9 g/day), and
increase is evident after 3 days of supplementation; EPA
and DHA are incorporated equally effectively [42]. Diet-
ary data for current n-3 and n-6 fatty acid intake was
gathered at all time-points, to assess stability of dietary
LC PUFA intake over the trial, a food frequency ques-
tionnaire (FFQ) was administered as a measure of typi-
cal nutrient intake over the preceding one-year period
at baseline and at Time 4, and historical seafood con-
sumption was also assessed. Cross-sectional associations
between these measures and outcomes will be
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investigated, and if there are differences between groups
at baseline or changes in n-3 or overall dietary intake
which differ significantly between the active and control
groups, then we will control for any potential effects of
this on outcomes. Table 1 summarises the data collected
at each time point.
Outcome measures
Primary outcome measures
Rate of change in cognitive performance, as measured
by latent variables for the cognitive constructs detailed
below.
Secondary outcome measures
Change in: MMSE; perceived health status, depressive
symptoms, positive and negative affect, life satisfaction,
self-reported cognitive functioning, and functional capa-
city, as assessed by the questionnaires below; blood
pressure; biomarkers of glucose, glycated haemoglobin,
triglycerides, total cholesterol, HDL, LDL, homocysteine,
CRP, MDA, and telomere length.
Cognitive test battery
No previous definitive evidence suggests which cognitive
domains may be amenable to change via n-3 LC PUFAs,
thus the test battery used in this study comprehensively
assessed all relevant domains that might benefit from a
nutritional intervention. The focus of the battery was on
constructs that are sensitive to age-related changes and
that are most strongly associated with functional status,
functional decline, and dementia.
Most of the cognitive domains were assessed using
tasks in which speed of response was the main outcome
measure. The psychometric properties of speed tasks
make them more sensitive to subtle cognitive changes
and obviate the need for parallel forms for repeated
assessment. These properties, together with evidence
that processing speed is integral to higher-order pro-
cesses such as reasoning [43], may be a key indicator of
changes in neural efficiency [44] and functional out-
comes [45], and is an important mediator of age-related
cognitive changes [46], make speed tasks ideal as out-
come measures to test the effect of a nutritional inter-
vention on cognitive performance in older-age.
With the exception of two individual tasks, at least
two measures of each cognitive construct were used to
indicate a latent construct for statistical analyses,
thereby reducing task-specific variance and increasing
construct validity and the reliability of assessment. The
cognitive constructs assessed were Reasoning, Working
Memory, Short-term Memory, Retrieval Fluency, Inhibi-
tion, Simple and Choice-Reaction Time, Perceptual
Speed, Odd-man-out Reaction Time, Speed of Memory
Scanning, Psychomotor Speed, Inspection Time, and
Knowledge. The latter two were measured by only one
task each and the knowledge measure was included as a
‘control’ task in that the construct it assesses does not
decline with age nor would it be expected to be modifi-
able by intervention. Excepting the tasks measured by
speed of response, parallel versions of each task were
presented at each assessment visit unless otherwise spe-
cified. For a detailed description of the test battery see
Appendix 1.
All measures were completed in small groups of up to
7 people, in CSIRO’s Cognitive Laboratory, and adminis-
tered by 2 trained research officers. The testing sessions
lasted approximately four hours and consisted of four
Table 1 Summary of measures assessed over the study duration.
Outcome measures and covariates Time points (months)
~ -3 0 6 12 18
MMSE x x x
Cognitive measures x x x x
Physical activity, functional capacity, and well-being measures x x x x
Height x
Blood pressure, weight x x x x
Erythrocyte membrane n-3 and n-6 fatty acid status x x x x
Serum folate and Vitamin B12, and plasma carotenoid levels x x
Lipids, glucose, glycated haemoglobin, homocysteine x x
Medications, supplement use, adverse events and health changes x x x x
ApoE genotype x
Inflammation (CRP), oxidative stress (MDA), and telomere length x x
Dietary data - general FFQ x x
Dietary data - n-3 consumption FFQ x x x x
Dietary data - historical seafood consumption FFQ x
Abbreviations: MMSE = Mini-mental state examination; n-3 = omega-3; n-6 = omega-6; FFQ = food frequency questionnaire; ApoE = Apolipoprotein E.
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sections of around 50 min duration, with a break of
approximately 10 min between each section. During this
break participants were provided with standard refresh-
ments, including decaffeinated tea/coffee. The speed
tasks were interspersed between the accuracy based
tasks and to also help minimise fatigue, paper and pencil
tasks were interspersed with computerised tasks, which
were administered in an adjacent room. The order of
tasks was fixed across participants and testing sessions.
Instructions and practice items preceded each test, and
questions were clarified before commencement.
Participant demographics
At study commencement, a questionnaire ascertained
the following demographic and health information: sex,
date of birth, and occupation (prior main occupation if
retired); diagnosed medical conditions and regularly
taken medications; supplement use and duration; and,
for women, the use of hormone replacement therapy. A
smoking questionnaire assessed current smoking status,
the number of cigarettes/cigars/pipes smoked per day,
and smoking history, from which pack years was derived
(number of pack years = (number of cigarettes smoked
per day × number of years smoked)/20) to measure life-
time direct smoking exposure. Changes to smoking
habits were captured at study end.
Information was updated regarding medical and health
details during the first and then subsequent visits to the
CSIRO clinic.
During the assessment sessions, questionnaires were
administered to gather other relevant demographic
information: highest level of education achieved, country
of birth and if relevant, the age of arrival in Australia
and years of speaking English, parents’ birth country
and occupations, perceived ethnicity, cultural determi-
nants of family diet in childhood, familial history of
diagnosed dementia, current income level (as per the
Australian census, 2006), and relationship status. Fre-
quency of computer use, handedness, and possible hear-
ing and vision impairments (including colour blindness)
were also recorded. Participants’ level of engagement in
day-to-day mental or cognitive activities was assessed by
self-reported minutes per week doing challenging puz-
zles, self-directed learning, managing finances, or teach-
ing/attending classes. At study end participants stated
which experimental group they thought they were in, to
assess adequacy of blinding.
Physical activity, functional capacity, and well-being
To assess changes in functional capacity and well-being,
and potentially control for any effect of changes in
mood or physical activity on cognitive functioning, vali-
dated questionnaires assessing everyday functioning
(The Late Life Function and Disability Instrument
[47,48]), depression (Centre for Epidemiology Studies
Depression Scale [49]), self-reported cognitive function-
ing (Cognitive Failures Questionnaire [50], Prospective
and Retrospective Memory Questionnaire [51]), subjec-
tive well-being (mood: Positive and Negative Affect
Scale-Extended [52]; life satisfaction: Diener’s Satisfac-
tion with Life Scale [53], the Personal Wellbeing Index
[54]), health-related quality of life (SF-36 [55], the sleep
scale from the Nottingham Health Profile [56]), and
physical activity (The Yale Physical Activity Survey [57])
were compiled as a general health and wellbeing ques-
tionnaire, which participants completed for each assess-
ment. See Appendix 2 for descriptions of the
questionnaires and derived scores.
Dietary Intake
The Victorian Cancer Council FFQ [58,59] was used to
measure average daily dietary intake, and a Polyunsatu-
rated Fatty Acid FFQ [60] was used to assess usual diet-
ary intake of n-3 and n-6 PUFAs. The PUFA FFQ was
administered in paper format and scored using the elec-
tronic version. Lifetime seafood intake was assessed via
the Lifetime Diet Questionnaire [61].
Anthropometry and blood pressure
Height was measured at baseline, using a wall-mounted
stadiometer (SECA, Hamburg, Germany) and weight
was measured at each assessment session using a cali-
brated digital precision scale (UC-321PBT; A&D Medi-
cal, Sydney, Australia). Body Mass Index was calculated
as weight (kg)/height (m)2 to examine as a potential
covariate. Blood pressure was measured in the left arm
and after the subject had been seated supine for 5 min-
utes, using an automated sphygmomanometer (Sure
Signs V3; Philips Medical Systems, Andover, MA), and
the average of three consecutive readings was used as
the measured value for each assessment.
Biochemical indicators
Blood was collected into Vacutainer tubes containing
EDTA, cooled to 4°C and separated into plasma (for
malondialdehyde and carotenoids analyses) and erythro-
cytes (for analysis of fatty acids) by centrifugation. Ery-
throcytes were washed twice with isotonic saline and
reconstituted to the original volume in water to lyse the
cells. For glucose analyses, plasma was separated from
blood collected into Vacutainer tubes containing EDTA
+ NaF. Serum was separated from clotted blood for
lipid analyses. Aliquots of plasma, serum and lysed ery-
throcytes were stored at -80°C until analysis.
Serum vitamin B12 and folate, plasma homocysteine,
and HbA1c were measured at an accredited pathology
laboratory (IMVS, Adelaide, Australia). Plasma glucose
and serum total cholesterol, triglycerides, HDL, and
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CRP were measured on a Hitachi 902 clinical analyser
using diagnostic kits (Roche Diagnostics, Australia). LDL
cholesterol was calculated using the Friedewald Equation
[62]. Plasma MDA was measured by a fluorescence high
performance liquid chromatography (HPLC) method as
detailed by Belobradjic et al [63].
Carotenoids were measured on a Shimadzu LC10
HPLC fitted with a refrigerated auto sampler and a
SPD-MV10 Avp photodiode array detector with a class
LC10 chromatography workstation. The chromato-
graphic separations of the fat soluble vitamins and caro-
tenoids were carried out on a Varian Microsorb-MV
reverse phase C18 column, 4.6 mm ID × 250 mm
length, 5 micron spherical particles [64].
The analysis of erythrocyte membrane fatty acids was
based on a method reported by Ridges et al. [65], which
uses a one-step extraction and transesterification proce-
dure [66]. Solid phase extraction on florisil (Sigma-
Aldrich Pty Ltd, Castle Hill, NSW Australia) was used
to clean up the toluene extract containing the fatty acid
methyl esters (FAME) after the transesterification proce-
dure. Briefly, the toluene was dried under nitrogen, resi-
due redissolved in hexane and loaded onto florisil. The
FAME were eluted from the florisil with 10% ether in
hexane, dried under nitrogen and re-dissolved in isooc-
tane. An aliquot was injected onto a bonded-phase vitr-
eous silica BPX70 column 30 m × 0.53 mm × 0.5
micron (SGE, Australia) in an Agilent 6890N gas chro-
matograph equipped with a cool on-column injector.
Peak identification was based on a comparison of reten-
tion times with Supelco 37 component FAME mix
47885-U (Sigma-Aldrich Pty Ltd, Castle Hill, NSW Aus-
tralia) and peak areas were measured using ChemStation
software.
Genomic Markers
ApoE genotyping was performed using Polymerase
Chain Reaction (PCR) - Restriction Fragment Length
Polymorphism method, as described by Hixson et al.
[67]. Absolute telomere length was measured by deter-
mining the number of TTAGGG hexamer repeats using




Latent growth curve modelling (LGCM) will be the
main analysis method used to assess the effect of the
intervention. LGCM is an appropriate and rigorous
methodology to employ for intervention studies that
aim to alter a developmental trajectory and has greater
power to detect an effect than models traditionally used
in examining interventions, such as ANCOVA or
repeated measures ANOVA [69].
Four equally-spaced testing time points were used in
this study because, firstly, four time points are required
to distinguish between different growth forms (e.g., lin-
ear, quadratic) and, secondly, four time points are esti-
mated to give adequate power. The cognitive domains
will be modelled as latent variables, providing the cogni-
tive factors prove to be measuring the same construct
across time, following the initial planned modelling of
the tasks and cognitive factors on baseline data using
confirmatory factor analysis (CFA). The main effect of
the intervention on each cognitive domain will initially
be assessed separately following Muthèn and Curran
[69]. The main intervention effect can be tested by mod-
elling the shape of the curve, for the time-points of a
construct, for treatment and control groups separately.
Both groups are constrained to the same normative
growth trajectory, and the treatment slope added to the
treatment group. Statistical significance of the mean of
the treatment slope indicates a significant main treat-
ment effect. Within this framework, further tests will
also examine interaction effects, to determine whether
the magnitude of the treatment effect varies as a func-
tion of initial cognitive status, and whether other factors,
such as carriage of the ApoE-e4 allele, sex, or initial n-3
status, moderate the treatment effect. Similar analyses
will be undertaken for well-being.
Power
Power was estimated based on a small effect size
(Cohen’s d) of .2, because there was no solid basis for
an expected effect size, and followed power analysis
based on LGCM of an artificial longitudinal treatment
dataset [69]. This effect size equated to a difference in
slope of .23 SD of the control group slope (set at 20% of
initial status). Power here refers to the power to detect a
difference between the treatment and control groups in
terms of mean rate of decline and/or in the variance of
the decline rate at an alpha level of .05. A total sample-
size of 350 was required for power of .84. To detect an
interaction effect of .40 (moderate size) between initial
status and treatment slope in the treatment group, with
a main effect of .2, required a sample-size ≌ 275. We
aimed for an initial sample of 420, allowing for an attri-
tion rate of approx. 17%, resulting in N = 350 at time 4,
giving sufficient power to detect the primary effects.
Data treatment of cognitive indicators
Treatment and analysis of reaction time data was con-
ducted only on trials with correct responses. Unfeasibly
long latencies on single trials and latencies less than 200
ms or greater than 3.5 intraindividual standard devia-
tions above the individual’s mean on a particular task
were set to missing, and individuals’ mean latencies then
recomputed. Considering the above factors, if a partici-
pant had less than 60% of valid trial data on a particular
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task, their mean reaction time for the task was set to
missing. Participants’ scores were also set to missing on
a particular speed task if their accuracy was less than
70% on that task. For the speed tasks and excepting the
inhibition tasks’ difference scores, the inverse of mean
correct latencies were used, to normalise the distribu-
tion [70] and to express performance as a work rate. For
all tasks (both speed and accuracy based), total or mean
reaction time scores for data for tasks not completed, or
not completed according to correct procedure, were
considered missing.
Modifications to cognitive test battery after baseline
assessment
Confirmatory factor analyses were planned on the base-
line data (N = 391) to assess the relationships between
the tasks and constructs and, in particular, to ensure no
empirical redundancy between any of the constructs.
The cognitive test battery was potentially to be abbre-
viated for future assessments, on the basis of the
outcomes.
CFA was performed separately on the baseline data for
the tasks assessed by accuracy and speed of response,
respectively, using full information maximum likelihood
estimation in AMOS 7, to deal with the small amount
of missing data. For the accuracy based tasks, latent
variables were specified for Fluid Intelligence, Working
Memory, Short-term Memory, Long-term Memory, and
Retrieval Fluency, indicated by the respective tasks spe-
cified in Appendix 1 under each construct. The latent
variable covariances were free to vary and the residual
variances of the immediate and delayed versions of the
two memory tasks were allowed to covary to account
for their shared methods. All loadings were of at least
moderate magnitude, significant, and in the expected
direction and the model fit the data well (c2 = 66.42, df
= 42, p = .010; Root Mean Square Error of Approxima-
tion (RMSEA) = .039, 90%CI [.019, .056]; Comparative
Fit Index (CFI) = .984; Akaike Information Criterion
(AIC) = 162.4); however, the covariance matrix among
the factors was not positive definite because the correla-
tion between Long-term Memory and Short-term Mem-
ory was near unity (r = .975). To examine whether both
factors were necessary, a model was specified without
Long-term Memory and with the delayed memory tasks
loading on Short-term Memory (c2 = 71.5, df = 46, p =
.009; RMSEA = .038, 90%CI [.019, .054]; CFI = .983;
AIC = 159.5). This model fit the data better. Because an
independent Long-term Memory factor could not be
identified, the indicators of Long-term Memory were
deleted and the model re-estimated (c2 = 53.8, df = 29,
p = .003; RMSEA = .047, 90%CI [.027, .066]; CFI = .979;
AIC = 125.8); this model also fit the data well and to
abbreviate the test battery the long-term memory
indicators, that is, the delayed word recall and delayed
face recognition tasks, were dropped from the test bat-
tery for future assessment sessions. This final model was
taken as the measurement model for the accuracy-based
tasks and is depicted in Figure 1.
For the speed-based tasks, the model specified latent
variables for Simple/Choice Reaction Time, Odd-man-
out Reaction Time, Inhibition, Speed of Memory Scan-
ning, and Psychomotor Speed, with the indicators for
each factor as specified under each construct in Appen-
dix 1. The model fit was acceptable (c2 = 171.4, df =
104, p < .001; RMSEA = .041, 90%CI [.030, .051]; CFI =
.979; AIC = 303.4) and, except for Inhibition, the indica-
tor loadings were of moderate to high magnitude, in the
expected direction, and significant; the loadings of the
Inhibition tasks were generally lower but all were signifi-
cant except Flanker, which was near zero (-.02). The
magnitude of the factor correlations ranged from .19 to
.70, all were in the direction indicating positive relation-
ships, and none was so high as to imply redundancy of
any factor. The Flanker task was deleted and the model
re-estimated (c2 = 155.9, df = 89, p < .001; RMSEA =
.044, 90%CI [.032, .055]; CFI = .979; AIC = 281.947); all
coefficients were significant and the fit statistics for this
model were similar but the AIC indicated better model
fit. Although the loading of Colour Stroop on inhibition
was also low (.18), given the more experimental nature
of this factor (ie., not an established unitary construct in
the literature) only the Flanker task was dropped from
the test battery for future assessments. Figure 2 depicts
the final speed measurement model.
In total, on the basis of the above analyses, three tasks
from the initial test battery were dropped from the bat-
tery for the subsequent assessments.
Conclusions
This methodology and protocol paper provides a
detailed overview of the design and implementation of a
double-blind, randomised, controlled trial assessing the
efficacy of a DHA-rich fish-oil supplement on slowing
cognitive decline, over 18-months, in cognitively-normal
older adults. This is one of the few trials to date to
examine the impact of n-3 LC PUFA supplementation
on cognitive decline in cognitively healthy older adults.
Advantages of the current study are the comprehensive
assessment of cognitive functioning and the multiple
measurement points, which allow for assessment of an
intervention effect on a trajectory, rather than effects at
a specific time point. The significance for society could
be wide-ranging if such an available and inexpensive
dietary treatment has the possibility to safely reduce
cognitive decline in ageing, given the links between cog-
nitive functioning and the societal and personal burden
of dependency and decreased quality of life in older age.
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Appendix 1: Cognitive test battery
Parallel versions of each task were presented at each assess-
ment visit unless otherwise specified. The Flanker task and
the delayed recall tasks for Face Memory and Word Mem-
ory were only presented at the first assessment because
these tasks were found not to adequately mark the expected
latent construct in confirmatory factor analyses of the base-
line results, conducted between assessments 1 and 2.
Tests were administered via paper-and-pencil or com-
puter. The order of presentation of tests is indicated in
parentheses following the name of the task below. All
computerised task scripts, excepting Inspection Time,
were written and/or modified using the software Inquisit
(v. 2©, Millisecond Software). The Memory Scanning
and Inhibition tasks were newly devised.
Knowledge
Vocabulary (#17). 20 items from forms 1 and 2 of the
standard, advanced, and extended range vocabulary tests
from ETS Kit of Factor-Referenced Tests [71] comprise
this multiple-choice task. A 4-minute time limit was
imposed.
Reasoning
Raven’s (Standard Plus) Progressive Matrices (#10) [72].
Stimuli are a three by three array of symbols, with the
bottom right hand symbol missing. Participants choose,
from options given below the matrix, which symbol logi-
cally completes the matrix. Twenty items, selected to
maintain progressive difficulty, were administered with a
ten-minute time limit. The same version was adminis-
tered at each assessment.
Letter Sets (#13). This task is from the ETS Kit of
Factor-Referenced Tests [71]. Stimuli consist of a ser-
ies of five, four-letter items, which follow a predeter-
mined alphabetical ordering. The task is to determine
the rule or pattern linking four of the items and cross-
out the item not fitting the rule. Fifteen items com-
prised this test, administered with a seven minute time
limit. The same version was administered at each
assessment.
Everyday Problems Test (#19) [73]. This test is an
objective measure of adults’ ability to solve problems of
daily living, presented as printed material, in seven
domains considered critical for independent living. The
seven domains, similar to those covered by the Instru-
mental Activities of Daily Living (IADL [74]), are health
(medications), meal preparation/nutrition, phone usage,
shopping, financial management, household manage-
ment, and transportation. Stimulus material is in three
formats - directions, charts, and forms - and number of
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Figure 1 Measurement Model for the tasks assessing level of cognitive performance. Final measurement model of the baseline data for
the accuracy-based tasks (c2 = 53.8, df = 29, p = .003; RMSEA = .047, 90%CI [.027, .066]; CFI = .979; AIC = 125.8). The Face Memory and Word
Memory indicators represent the immediate recall/recognition versions. Correlations are represented by double-headed arrows.
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each item, a stimulus (e.g., prescription medication label,
phone fee chart, mail-order form) is presented from
which the participant must derive the answer through
reasoning, to the accompanying item question. The test
at each time point comprised 21 multiple-choice items
(selected from the full-test 84-item pool), with a 15 min
time limit imposed.
Retrieval Fluency
Word Endings (#18). This test is derived from the ETS
Kit of Factor-Referenced Tests [71]. The task is to write
down as many words ending with a specific set of letters
(e.g., ‘in’). The score is the number of valid words writ-
ten within 2 minutes.
Retrieval Fluency (#21). This test is derived from the
Woodcock-Johnson III Tests of Cognitive Ability [75].
Participants have to write as many words falling within
a given category as possible, in two minutes. The score
is the number of things written, bar repeats.
Short-term Memory
Face Memory - immediate recall (#1). This task, derived
from Herzmann, Danthiir, Schacht, Sommer, and Wil-



























































Figure 2 Measurement Model for the tasks assessing speed of cognitive performance. Final measurement model of the baseline data for
speed tasks (c2 = 155.9, df = 89, p < .001; RMSEA = .044, 90%CI [.032, .055]; CFI = .979; AIC = 281.947). Correlations are represented by double-
headed arrows. Abbreviations: RT = Reaction Time; MT = Movement Time.
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are presented with 1.5 mins to study them. Each trial in
the subsequent test period presents one of the studied
faces next to a completely new face and the task is to
indicate which face was the studied face.
First and Last Names (#11). In this paired associates
test, derived from the ETS Kit of Factor-Referenced
Tests [71], participants are given 2.5 mins to study a list
of 15 first and last name pairs. They are then shown
only the last names and allowed 1.5 mins to write down
the associated first names.
Word Memory - immediate recall (#2). Word list A
from the Rey Auditory Verbal Learning Test [77] was
presented via computer at the first assessment and par-
allel word lists were presented for subsequent sessions.
15 words (nouns) were presented, one at a time, on
screen for one sec duration, with an inter-trial interval
of one sec. Immediately after presentation of the word-
list, participants write down, in any order, as many of
the words recalled.
Long-term memory
Face Memory - delayed recall (#29). Approximately 3.5
hrs after presentation of the initial Face Memory task,
participants were tested again on the faces studied in
that task. Each trial presents one of the studied faces
next to a completely new face. The task is to indicate
the face that was studied in the initial study phase of
the Face Memory task.
Word Memory - delayed recall (#6). Approximately 30
mins after presentation of the initial Word Memory
task, participants write down as many words as they can
recollect from the list, in any order.
Perceptual Speed
Digit-Symbol Substitution (#12); from the revised ver-
sion of the Wechsler Adult Intelligence Scale [78]. A
code with nine symbols, each uniquely associated with
one of the digits “1” through to “9”, is presented at the
top of the page, with rows of only the digits below. The
task is to fill in beneath each digit, in order of presenta-
tion, as many of the corresponding symbols as possible,
within 90 secs. The score is the number of correct
answers.
Finding As (#9); from the ETS Kit of Factor-Refer-
enced Tests [71]. Participants are required to examine
columns of words; each column has five words contain-
ing the letter “A.” The task is to place a line through
words that contain “A” and ignore those that don’t. The
score is the number of words marked correctly within
the one-minute time limit.
Number Comparison (#20); from the ETS Kit of Fac-
tor-Referenced Tests [71]. This task consists of two col-
umns of number-pairs, the numbers varying from 3 to
12 digits in length. Participants are required to place a
cross between pairs of numbers if they are not identical.
The score is the number marked correctly within the
one and a half minute time limit.
The following tasks are all computerised tasks.
Working Memory
Each of the following tasks presents a processing task
prior to the stimulus to be remembered. A reminder of
the response keys for the processing task is present on
the screen throughout. Each trial consists of two to five
screens, depending on the difficulty level of the trial,
prior to the cue to recall the stimuli. 12 items comprise
the test, with three trials of set-size two, and two each
of set-sizes three to five. The score is the mean of the
proportion of numbers recalled in the correct serial
position for each item.
Counting Span (#15) [79,80]. Participants must
remember digits while concurrently undertaking a
counting task. For each screen, a number of blue circles
and squares, and green circles are shown. The partici-
pant must count and remember the number of blue cir-
cles in each screen, and then press a key indicating
whether the number was odd or even. After a response,
the next set of figures is presented and after the last set,
participants have to serially recall the number of blue
circles in each of the preceding displays, responding
using the keyboard and mouse. If a participant does not
correctly recall the serial position of a minimum of one
digit in a set-size, the task ends.
Operation Span (#4) [79,80]. In this task, participants
remember words (nouns) while concurrently solving a
simple arithmetic problem. Each screen presents a
maths equation followed by a word, of the form: “DOES
(6 × 2) - 5 = 7? CLASS”. Participants look at the word
then press a key indicating whether the equation was
correct or not. After the response, the next equation/
word screen appears and after the final screen, partici-
pants write down the words recalled in the correct serial
position. Parallel word sets were used in each session.
Inspection Time
A windows based version of Inspection Time (#31) [81]
was administered. Participants repeatedly view a target
stimulus consisting of two vertical lines, joined at the
top by a horizontal line, for varying durations. One ver-
tical line is always shorter, with equiprobability. For
each trial, the participant indicates by mouse-press
whether the shorter line was on the left or right side.
Using an adaptive staircase algorithm [82], a partici-
pant’s inspection time is defined as the duration of sti-
mulus exposure (in ms) which has an associated
probability of 79% of making a correct response.
For the following reaction time tasks, unless otherwise
specified, a practice session of 12 trials precedes the
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start of each test and each task consists of 30 trials.
Feedback (accuracy) is presented after each practice
trial. The stimuli in both the practice trials and the test
proper are balanced such that an equal number of each
potential response is required, and for tasks with more
than one condition (e.g., Colour Stroop), task-relevant
stimulus characteristics are also balanced across
conditions.
Simple and Choice-reaction Time
A simple (#3) and two- (#5) and four-choice (#8) reac-
tion time tasks are included, modified from Danthiir,
Wilhelm, and Roberts (Further evidence for a multifa-
ceted model of mental speed: Factor structure and valid-
ity of computerised tasks, submitted). The stimuli in
these tasks are digits, each associated with arrows point-
ing in different directions. In all tasks, the stimulus-
response coding is present at the top of the screen. Par-
ticipants must press the appropriate arrow response key,
depending on which number is displayed. The number
of possible responses increases from one in the simple
reaction time task to four in the 4-choice reaction time
task.
Odd-man-out (OMO) Reaction Time
Two variants of the OMO task (Letter (#14) and Num-
ber (#23) OMO, modified from Danthiir et al. (Danthiir,
Wilhelm, & Roberts: Further evidence for a multifaceted
model of mental speed: Factor structure and validity of
computerised tasks, submitted) are included. The OMO
task requires an additional discrimination compared to
typical CRT tasks. A string of eight equidistant stimuli
are presented on screen. In each string, three stimuli are
identical (ie., targets) and different from the other five.
Two of the targets are always closer together in relation
to the position of the third target. The task is to press a
key to indicate if the odd-man-out (i.e., the target furth-
est from the two closer target stimuli) is to the left or
right of the other targets.
Speed of Memory Scanning
Two variants of Sternberg’s memory scanning paradigm
[83] were devised, measuring speed of scanning items in
short-term memory; one task using numbers (#7) as sti-
muli and the other, letters (#16). A string of two to five
stimuli are presented simultaneously on the screen for
2200 ms. A probe stimulus is then presented and
remains onscreen until participants press a key to indi-
cate whether the probe was in the preceding string.
Inhibition (or Interference Control)
The following tasks that were devised tap inhibitory pro-
cesses, also known as interference control or inhibition
of prepotent responses. In all tasks the stimuli vary by a
task-relevant and -irrelevant characteristic. The task-
irrelevant characteristic is linked (e.g., spatially) via auto-
matic prepotent response to the response dimension,
providing two or three stimulus-response compatibility
(SRC) conditions depending on the task; congruent,
incongruent, and sometimes neutral. Trials are balanced
in number across stimulus response congruency (SRC)
condition and stimulus. During the test, if an incorrect
response was given twice in a row for a particular trial-
type (e.g., a green left oriented stimulus) a reminder of
the correct response keys was presented for 5 sec.
Simon Task (#30). The typical Simon effect refers to
the interference (manifesting both in delayed RT and
increase in errors) experienced when the response
required by a task is spatially opposite to the location of
the stimulus, creating a stimulus-response conflict [84].
Stimuli in this task were a red or green circle, presented
on the left or right side of the screen. Participants press
the right SHIFT key if the stimulus is green and the left
SHIFT key if it is red. Two conditions are present in
this task; stimulus-response congruent, where the loca-
tion of the circle is on the same side as the required
response (e.g., a green circle on the right side of the
screen) and incongruent, where the location of the circle
is on the opposite side of the required response (e.g., a
green circle on the left side of the screen). The task
comprises 60 trials. The dependent variable in analyses
is the difference in RT between the congruent and
incongruent conditions.
Colour Stroop Task (#22). This task is based on the
well-known Stroop effect [85]. Stimuli are the words
blue, yellow, note, or engine, coloured yellow or blue,
presented one at a time on the computer screen. The
task is to press the appropriate key indicating the colour
the word is displayed in. Three conditions are present in
this task: stimulus-response congruent, where the word
matches the colour it is presented in (e.g., the word
“YELLOW, “ coloured yellow); incongruent, where the
word does not match the colour it is presented in (e.g.,
the word “YELLOW, “ coloured blue); and neutral,
where the word is not a colour word (e.g., the word
“ENGINE, “ coloured yellow). 90 trials are presented
and the dependent variable in analyses is the difference
in RT between the neutral and incongruent conditions.
Spatial Stroop Task (#25). This task is a measure of
the so-called spatial Stroop effect (e.g., [86]). The word
LEFT or RIGHT is presented on the left or right side of
the screen. Participants press the Right SHIFT key for
the word “RIGHT” and the Left SHIFT key for the word
“LEFT.” There are two conditions in this task; stimulus-
response congruent, where the word matches the side it
is presented on (e.g., the word LEFT presented on the
left side of the screen) and incongruent, where the word
does not match the side it is presented on (e.g., the
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word LEFT presented on the right side of the screen).
60 trials comprise this task and the dependent variable
in analyses is the difference in RT between the congru-
ent and incongruent conditions.
Flanker Task (#24). The flanker effect refers to the
influence of flanking distracter stimuli on target identifi-
cation, whereby identification is facilitated by response-
congruent flankers and inhibited by response-incongru-
ent flankers [87]. The target in this case was either the
letter “S” or the letter “H, “ presented in the centre of
the screen, flanked simultaneously by two letters dis-
played either side of the target letter. If the target letter
is an “H” participants press the left SHIFT key and if
the target letter is an “S” participants press the right
SHIFT key. There are three different conditions: the
congruent condition where the flanking letters are all
the same as the target letter, the neutral condition
where the flanking letters (the letter “P”) are different
from either of the target letters, and the incongruent
condition where the flanking letters are the alternative
target letter (i.e. if the target letter is “H” the flanking
letters are “S"s and vice-versa). 90 trials are presented.
The dependent variable in analyses is the difference in
RT between the neutral and incongruent conditions.
Psychomotor Speed
For these tasks, participants use only the index finger of
their preferred hand. For each task, ten practice trials
and 20 test trials are given. The dependent variable is
the time taken (in ms) between key presses. Following
the prompt to begin, participants press either one key,
repeatedly (Simple Movement Time task (#26)), or two
keys (vertically adjacent - Up Movement Time task
(#27); diagonally adjacent - Diagonal Movement Time
task (#28)) as quickly as possible.
Appendix 2: Functional Capacity, physical activity,
and well-being questionnaires
Unless stated otherwise, if the original questionnaire
specified the time-period to which the questions were
directed, this was specified as one month in the current
study; the exception was questionnaires relating to
mood, which were maintained as pertaining to the pre-
vious week to assess state, as opposed to trait, affective
states.
Health status
The Australian SF-36 version 2 [55] (SF36V2) health
survey standard form was used as a measure of health-
related quality of life. The SF36V2 comprises 36 items
from which are derived eight norm-based scale scores:
Physical Function, Role Physical, Bodily Pain, General
Health, Vitality, Social Function, Role Emotion, and
Mental Health. Two summary scale scores are derived
from sums of the eight scale scores, weighted by factor
score coefficients, representing physical and mental
health (physical component score (PCS) and mental
component score (MCS)). The eight scale scores were
normed according to 2004 data from a large South Aus-
tralian population-based health survey [88,89] and the
PCS and MCS were weighted using factor score coeffi-
cients computed in this population. On all scales, a
higher score indicates better health.
The SF-36 was supplemented with the sleep scale
from the Nottingham Health Profile [56], a generic vali-
dated health-related quality of life measure, to assess
quality of sleep. The scale consists of five items
weighted for severity, which have a maximum sum of
100. Participants answer yes or no to each item and the
weights are added on items with a positive response; the
higher the score the greater the health problem.
Physical activity
The Yale Physical Activity Survey is a validated [57,90],
interviewer-administered questionnaire specifically
designed to be sensitive enough to capture the lower-
intensity range of physical activities of older adults. It
assesses the level of activity during a typical week in the
last month. Minor changes to instructions were imple-
mented to adapt the survey to a format suitable for self-
completion. The questionnaire assesses work-, yard-
work-, exercise-, caretaking-, and recreational-related
physical activity, expressed as minutes per week, as well
as current participation in several different types of
activity categories believed to reflect physical activity
dimensions. A total of eight indices are derived, three
summary and five subscale indices, and a seasonal
adjustment score can be calculated: 1) Total Time Sum-
mary Index, expressed as hours per week; 2) Energy
Expenditure Summary Index, expressed as kcal/week-1;
and 3) Activity Dimensions Summary Score (sum of five
subscale indices, vigorous activity, leisurely walking,
moving, standing, and sitting, each derived by multiply-
ing frequency score by duration score for each activity
type and then multiplied by a weighting factor (based
on relative intensity of activity), expressed as a unit
score), expressed as total units.
Depression
Depression was measured by the Centre for Epidemiol-
ogy Studies Depression Scale (CES-D) [49], a 20-item
tool measuring depressive symptoms in the general
population; it has been extensively validated, including
on older adults [91-93] and is widely used as a screening
measure. Frequency of occurrence of symptoms is
reported for the past week (as in original) and a higher
score is indicative of more depressive symptoms, with a
maximum score of 60; scores of 16 to 26 are considered
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indicative of mild depression and scores of 27 or more
indicative of major depression. Because the CES-D uses
a 4-point response scale it is more likely to be sensitive




The Positive and Negative Affect Schedule - extended
version [52], is a widely validated 60-item scale that
assesses two broad mood factors - positive and negative
affect - as well as 11 specific affects. Participants indi-
cated on a 5-point Likert scale the extent to which they
had experienced the listed emotions over the last week,
with higher scores indicating greater affect.
Life satisfaction
Two measures of life satisfaction were administered to
participants; Diener’s Satisfaction with Life Scale
(SWLS) [53] and the Personal Wellbeing Index (PWI)
[54]. Both of these measures were included to assess
cognitive rather than affective assessments of subjective
wellbeing.
The SWLS assesses respondents’ global evaluation of
life satisfaction by stating their level of agreement with
five statements regarding their life, using a seven point
Likert scale. The total score represents the extent of glo-
bal life satisfaction, with higher scores indicating greater
satisfaction and a maximum score of 35; normative data
are available for diverse populations including older
adults. The scale has been shown to be sensitive to pos-
sible changes in levels of life-satisfaction over time due
to the occurrence of positive and negative life-experi-
ences [94].
The PWI scale measures subjective wellbeing as an
aspect of quality of life. The scale consists of eight items
assessing satisfaction with various aspects of life and
participants rate their level of satisfaction on an 11-
point Likert Scale. These eight domain scores are
summed to yield an average score which represents sub-
jective wellbeing, higher scores indicative of greater
satisfaction, with a maximum of 100.
Self-reported cognitive functioning
Self-reported cognitive functioning in everyday situa-
tions was assessed by the Cognitive Failures Question-
naire (CFQ) [50] and the Prospective and Retrospective
Memory Questionnaire (PRMQ) [51].
The CFQ comprises 25 questions measuring self-
reported failures in everyday perception, memory, and
motor function. Participants rated on a 5-point Likert
scale the frequency of such events over the last 4 weeks.
A total score is typically derived, measuring proneness
to everyday slips and errors, with higher scores indicat-
ing greater perceived frequency of mistakes with a
maximum score of 100. However, an investigation of the
latent structure of the CFQ, using a large representative
adult sample, suggests its items assess three constructs -
Forgetfulness, Distractibility and False Triggering -
which are sensitive to age-effects [95].
The PRMQ is a validated [51,96-98] self-report mea-
sure, comprising 16 questions, divided equally to assess
the frequency of occurrence of prospective and retro-
spective memory errors in everyday life. Participants
were asked to assess the frequency of these occurrences
over the last 4 weeks, on a 5-point Likert scale. The
PRMQ has been found to have a tripartite latent struc-
ture consisting of a general memory factor plus orthogo-
nal specific factors of prospective and retrospective
memory [98,99], thus the PRMQ total scale can be used
as a measure of general self-rated memory or specific
memory scores can be derived. The maximum total
score is 80, with higher scores equating greater per-
ceived frequency of memory mistakes.
Functional Capacity
The Late Life Function and Disability Instrument
[100,101] (LLFDI) was designed to assess meaningful
change in functioning and disability in older community
dwelling adults. Concurrent and predictive validity of
the LLPDI has been assessed [102].
The Physical Function component of the LLFDI [101]
comprises 32 items measuring the level of difficulty
experienced in performing specific activities as part of
daily routines. The activities are divided into three
domains: basic lower extremity functioning, advanced
lower extremity functioning, and upper extremity func-
tioning, with additional questions for users of assistive
devices. Respondents rate the difficulty experienced on a
five-point Likert scale; all items can be added to derive
a total functioning score, with a maximum of 160 and
higher scores indicative of better physical functioning.
The Disability component of the LLFDI [100] comprises
16 items measuring two dimensions: the frequency of per-
formance of specific activities as part of daily routines, and
the extent of limitation experienced in performing the
activities. Respondents rate the frequency of performance
and the extent of limitation experienced on a five-point
Likert-type scale. Two sub-domains are identified within
each dimension: Frequency dimension - 1) Social role
(performance of various social and community tasks) and
2) Personal role (performance of various personal tasks);
Limitation dimension - 1) Instrumental role (activities at
home and in the community) and 2) Management role
(tasks that involve minimal mobility or physical activity).
Distinct summary scores can be calculated to represent
the Limitation and the Frequency dimension, each with a
maximum score of 80 and higher scores indicating less
limitation and greater frequency, respectively.
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Endnotes
a The current trial commenced prior to completion of
either of those trials.
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